Munafa Stock Market Course + Intraday & FNO calls 
MA NEWS why is Mastercard Incorporated price falling or rising
MA NEWS reasons for why stock price of Mastercard Incorporated is falling or rising
MA Mastercard Incorporated is falling or rising technical reasons
Technical analysis forecast of Mastercard Incorporated Stock is that its in a uptrend for shortterm, and I will avoid taking a SHORT or SELL trade in this stock. Look for opportunities to BUY or go LONG in Mastercard Incorporated MA at this time. Stock is rising and might rise more.
It appears as if Mastercard Incorporated MA gave a large move recently.
Stock of Mastercard Incorporated (MA) is trading above an important moving average line, and it has been above this line for quite some time now. This is a good sign, and the stock might keep rising and move higher!
My analysis of Mastercard Incorporated is bullish for shortterm, but trade for tomorrow is selective. Take a BUY trade only if Mastercard Incorporated stays above 609.7, but if it comes below 609.7, then a intra day sell could be more profitable.
If you take a sell trade below 609.7, then use 609.7 as stoploss and 587.13 as target. However if you take a buy trade in Mastercard Incorporated, then use 609.7 as stoploss and 636.7 as target.
MA Mastercard Incorporated is falling or rising NEWS fundamental reasons
Solara Active Pharma share price zooms 16% on Q2 turnaround; H1 net up 103x Solara Active Pharma Sciences reported a consolidated net profit of ?28.59 crore in Q2FY27 and ?44.70 crore in H1FY27. It posted a loss of ?9.29 crore in Q2FY26 and profit of ?0.42 crore in H1FY26. - NEWS as on 2026-10-16 business-standard.com
Mankind Pharma to acquire 70% in Belgian biotech firm for €48 million Deal marks entry into next-generation CAR-T cancer therapies as company expands global innovation ambitions - NEWS as on 2026-10-15 business-standard.com
Indian companies must invest in R&D, move from generics to innovation-led industry: Pharma leaders Indian pharmaceutical leaders emphasize the need for investment in innovation to transition from generics to innovative products. They highlight the importance of regulatory reforms and a strong ecosystem for research and development. Industry executives m - NEWS as on 2026-10-05 indiatimes.com
Kuku revenue jumps sixfold to ?1,484 crore as AI fuels microdrama expansion The Kuku TV and Kuku FM parent reported FY26 net revenue of ?1,484 crore and a profit of ?182 crore, as it builds a 1,000-member AI-led production unit ahead of its planned IPO - NEWS as on 2026-10-03 business-standard.com
Franco-Nevada Sees 45% Growth if Cobre Panama Restarts MarketBeat Week in Review – 08/10 - 08/14Franco-Nevada (NYSE:FNV) outlined its approach to profitable growth, citing a focus on return on capital, flexible financing structures and partnerships with operating teams, while highlighting potential produ - NEWS as on 2026-10-01 nasdaq.com
RIL Q2 Results: Nuvama sees 17% EBITDA growth, led by O2C biz. Here’s what to expect Reliance Industries is expected to report 17% year-on-year growth in Q2FY27 EBITDA to Rs 53,700 crore, led by stronger refining margins and higher throughput, according to Nuvama Research. While the O2C business is likely to drive near-term earnings, New E - NEWS as on 2026-10-01 indiatimes.com
Expanding innovative portfolio may drive gains for Sun Pharma stock Lerodalcibep licensing deal, growth in the US portfolio and tariff relief offer triggers, while the proposed Organon acquisition could broaden its global reach - NEWS as on 2026-09-29 business-standard.com
Sun Pharma bags rights to .7 billion cholesterol drug market globally Sun Pharma will commercialise and manufacture LIB Therapeutics' once-monthly cholesterol drug outside the US and China after its EU approval - NEWS as on 2026-09-28 business-standard.com
Jagsonpal Pharma to acquire Group Pharma’s wellness portfolio Jagsonpal Pharmaceuticals has signed a business transfer agreement to acquire the wellness portfolio of Group Pharmaceuticals. The acquisition is valued at an initial consideration of Rs 23.7 crore along with an additional amount based on future sales. Thi - NEWS as on 2026-09-24 indiatimes.com
MF Tracker: HDFC Pharma & Healthcare Fund tops equity MFs at 25% in 1 year. Should investors chase the rally? HDFC Pharma and Healthcare Fund recorded an impressive 25% return in the last year, surpassing its category average across various time frames. The robust performance is primarily due to heightened demand for generic drugs and recent FDA approvals. Investo - NEWS as on 2026-09-22 indiatimes.com
More announcements and NEWS
MA Mastercard Incorporated current price & indicator signals
Recent prices of MA Mastercard Incorporated are as follows: Daily volume is divided by 10 day averaged volume
| Date | Close | Range | Change % | Volume |
| 19 Mon Oct 2026 | 616.40 | 608.59 to 618.00 | -0.17% | 0.99 times |
| 16 Fri Oct 2026 | 617.42 | 613.32 to 622.49 | 0.18% | 1.15 times |
| 15 Thu Oct 2026 | 616.32 | 607.06 to 619.80 | 2.17% | 1.42 times |
| 14 Wed Oct 2026 | 603.24 | 600.65 to 606.61 | -0.26% | 1.08 times |
| 13 Tue Oct 2026 | 604.80 | 597.13 to 605.60 | 1.63% | 1.24 times |
| 12 Mon Oct 2026 | 595.09 | 590.21 to 598.95 | 1.01% | 0.97 times |
| 09 Fri Oct 2026 | 589.14 | 574.00 to 591.28 | 2.5% | 0.81 times |
| 08 Thu Oct 2026 | 574.76 | 568.49 to 581.59 | 0.82% | 1.13 times |
| 07 Wed Oct 2026 | 570.06 | 567.00 to 573.71 | 0.61% | 0.62 times |
| 06 Tue Oct 2026 | 566.58 | 562.14 to 568.93 | 0.35% | 0.76 times |
| 05 Mon Oct 2026 | 564.59 | 551.15 to 565.87 | 2.23% | 0.8 times |
| 02 Fri Oct 2026 | 552.26 | 545.41 to 554.68 | 0.41% | 0.82 times |
Videos related to: MA NEWS why is Mastercard Incorporated price falling or rising
Hindi Basics How To Trade In FnO Futures Options Stock Market
- NYSE Screeners
- NYSE Daily Screener
- NYSE Weekly Screener
- NYSE Monthly Screener
- Support & Resistance
- NYSE Shares Near Support
- NYSE Shares Near Resistance
